HC Wainwright Has Pessimistic Outlook of PLX FY2027 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a research report issued on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.11 per share for the year, down from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.06 EPS.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $2.67 on Thursday. The company has a market cap of $215.13 million, a PE ratio of -20.54 and a beta of 0.02. The business has a 50-day simple moving average of $2.42 and a two-hundred day simple moving average of $2.33. Protalix BioTherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $3.19.

Hedge Funds Weigh In On Protalix BioTherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PLX. BlackRock Inc. purchased a new stake in Protalix BioTherapeutics during the 2nd quarter worth approximately $9,429,000. Geode Capital Management LLC lifted its stake in shares of Protalix BioTherapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 830,054 shares of the company’s stock worth $1,494,000 after buying an additional 10,277 shares during the period. State Street Corp lifted its stake in shares of Protalix BioTherapeutics by 17.4% during the fourth quarter. State Street Corp now owns 585,261 shares of the company’s stock worth $1,053,000 after buying an additional 86,714 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Protalix BioTherapeutics by 932.7% during the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock valued at $644,000 after buying an additional 268,099 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Protalix BioTherapeutics by 159.0% in the 1st quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock worth $753,000 after acquiring an additional 180,702 shares during the last quarter. 16.53% of the stock is owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.